Cure-First
Cure-First is a nonprofit that grows organoids from a patient's tumour and screens them against dozens of anticancer drugs, and makes the results available to patients directly.
Overview
Cure-First offers organoid generation from patient tumour tissue and drug screening of more than 47 anticancer agents drawn from a library of over 200, as a nonprofit and patient-accessible service according to Future of Cancer Care Today.
Similar pages
not linked directly; found by shared links- Company2cureX
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanySageMedic
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanySpeciCare
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanyFirst Ascent Biomedical
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyKYAN Technologies
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyStoreMyTumor
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyTravera
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyKiyatec
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.